Early clinical data regarding MRTX1719 show activity across different tumor types, with responses seen in patients with MTAP-deleted pleural mesothelioma, melanoma, gallbladder adenocarcinoma, NSCLC, and malignant peripheral nerve sheath tumors [56]. This evidence concerns the gene MTAP and pleural mesothelioma.